Emergent BioSolutions, Inc. has submitted an IND application with the FDA for its Anthrax Immune Globulin (AIG) product candidate. AIG is a therapeutic treatment for patients with symptoms of anthrax disease resulting from the release of anthrax toxins into the body. Pending the FDA’s 30-day review period, the company expects to begin a clinical trial this year to evaluate the safety and pharmacokinetics of AIG in more than 100 healthy volunteers. “The filing of this IND for our...